BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

≡

論壇議程總覽

2025 創新科技論壇

​​

2025 Innovation Forum Agenda

Date July 23-25, 2025

Venue July 23 Room 701C, 7F, TaiNEX2
July 24-25 Room 401, 4F, TaiNEX1

Day 1 - Wednesday, July 23Room 701C, 7F, TaiNEX2
Day 2 - Thursday, July 24Room 401, 4F, TaiNEX1
Day 3 - Friday, July 25Room 401, 4F, TaiNEX1

14:10 – 15:40

Session A-1 – New Therapeutic Modalities

Session A-1 is a deep dive into the latest therapeutic innovations, showcasing next-generation approaches reshaping modern medicine. Speakers will present translational breakthroughs in targeted therapies, as well as cutting-edge developments in nucleic acid therapeutics, spotlighting their potential in precision medicine. Other topics covered include accelerating therapeutic pipelines from lab to market, and the latest oncology and hematology therapies. This session promises a dynamic exchange on how novel modalities are redefining treatment landscapes and improving patient care worldwide.
14:10 – 14:15

Opening Remarks

  • Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
14:15 – 14:35

Topic TBC

  • Mohamed EI-Sayed, Chief Scientific Officer, Nucleic Acid Therapeutics Initiative (NATi), A*STAR, Singapore
14:35 – 14:55

Topic TBC

  • Sherry Ku, Founder and President, Good Management Consulting Inc; Consulting Expert, Biomedical Translation Research Center, Academia Sinica
14:55 – 15:15

Taking an ADC into the Cancer Clinic: Medical Considerations

  • Christine dela Cruz, Director, Medical Apairs, Therapeutic Expertise, Oncology and Hematologym, ICON Biotech
15:15 – 15:35

Panel Discussion

Moderator:

  • Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

Panelist:

  • Mohamed EI-Sayed, Chief Scientific Officer, Nucleic Acid Therapeutics Initiative (NATi), A*STAR, Singapore
  • Sherry Ku, Founder and President, Good Management Consulting Inc; Consulting Expert, Biomedical Translation Research Center, Academia Sinica
  • Christine dela Cruz, Director, Medical Apairs, Therapeutic Expertise, Oncology and Hematologym, ICON Biotech
15:35 – 15:40

Closing Remarks

  • Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan

16:00 – 17:30

Session A-2 – Gene and Cell Therapies- Advanced Manufacture and Beyond

Session A-2 explores the rapidly-evolving frontier of gene and cell therapy manufacturing, focusing on innovation, scalability, and regulatory alignment. Topics covered will include Taiwan’s strategic role in next-gen biomanufacturing; technical breakthroughs driving production efficiency and therapeutic consistency; addressing the balance between fast-paced technology and regulatory rigor; and an examination of the field of clinical translation and real-world applications. This session promises a comprehensive look at how manufacturing is adapting to meet the complex demands of advanced therapies.
16:00 – 16:05

Opening Remarks

  • David Chang, CEO, Taiwan Bio-Manufacturing Corporation (TBMC)
16:05 – 16:20

Topic TBC

  • Ann Lee, Chief Technical Officer, Prime Medicine
16:20 – 16:35

Overcoming Allogenic Immune Rejection

16:35 – 16:50

Opposites Attract: Fast Technology & Deliberate Regulatory: How can manufacturing adapt to meet therapeutic demand?

  • Matthew Hewitt, Vice President, CTO Manufacturing Business Division, Charles River Laboratories
16:50 – 17:05

Topic TBC

  • Jeffrey Chou, Senior Vice President, Clinical Science, Iovance Biotherapeutics
17:25 – 17:30

Panel Discussion

Moderator:

  • David Chang, CEO, Taiwan Bio-Manufacturing Corporation (TBMC)

Panelists:

  • Ann Lee, Chief Technical Officer, Prime Medicine
  • Snehal Patel, Executive Vice President and Chief Technical Officer, Sana Biotechnology
  • Matthew Hewitt, Vice President, CTO Manufacturing Business Division, Charles River Laboratories
  • Jeffrey Chou, Senior Vice President, Clinical Science, Iovance Biotherapeutics

09:00 – 10:30

Session A-3 – AI & Translational Medicine

Session A-3 spotlights the transformative role of AI in accelerating translational medicine and drug discovery. Speakers will uncover how to better integrate AI in biomedical research; how machine learning enhances cross-dataset drug discovery; AI’s potential in population-level healthcare; and an examination of data-driven public health strategies. Join us as thought leaders demonstrate how AI is reshaping research, improving precision, and bridging discovery to clinical application in unprecedented ways.
09:00 – 09:05

Opening Remarks

09:05 – 09:25

AI-Powered Alignment of High-Content Screening Data: Accelerating Drug Discovery Through Cross-Dataset Learning

09:25 – 09:45

Topic TBC

09:45 – 10:05

Topic TBC

  • Feng-Chi Chen, Executive Director, Forum & Deputy Director and Investigator, Institute of Population Health Sciences, National Health Research Institutes
10:05 – 10:30

Panel Discussion

Moderator:

  • Hsing-Pang Hsieh, Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes

Panelists:

10:40 – 12:15

Session A-4 – Taiwan BIO Awards-Successful Stories

Join us as this year's Taiwan BIO Awards winners across all categories present their companies and innovations, and unveil the secrets to their success! Congratulations to all this year's well-deserved winners.
10:40 – 12:15

Sharing the Experience of Biotech Success 2025 Taiwan BO Awards Winners:

- Outstanding Company of the Year

- Emerging Company of the Year

- Startup of the Year

- Innovation of the Year

12:25-13:55

Session A-5 – CMC Program Design: Pioneering Biologics Development Excellence

Session A-5 delves into strategic Chemistry, Manufacturing, and Controls (CMC) program design as the cornerstone of biologics development success. Experts from across the biopharmaceutical value chain will explore best practices for building robust, scalable, and regulatory-compliant CMC frameworks that accelerate biologic innovation from early development through commercialization. The session will highlight the integration of advanced analytics, platform technologies, and quality-by-design principles to streamline development timelines while ensuring product integrity and global market readiness. With a focus on collaboration between R&D, manufacturing, and regulatory teams, this session will offer a roadmap for achieving excellence and agility in today’s competitive biologics landscape.
12:25 – 12:30

Opening Remarks

  • Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals
12:30 – 12:50

Topic TBC

  • Stephen Lam, CEO, Tanvex
12:50 – 13:10

Topic TBC

  • Jennifer Kuan, Vice President of Taiwan Operations, Bora Pharmaceuticals
13:10 – 13:30

Topic TBC

  • Speaker Inviting, Shine On Bio
13:30 – 13:50

Topic TBC

  • Vu Truong, Founder & CEO, Aridis Pharmaceuticals
13:50 – 13:55

Closing Remarks

  • Bobby Sheng, Chairman & CEO, Bora Pharmaceuticals

14:10 – 15:40

Session A-6 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives

Session A-6 will explore the expanding frontier of antibody derivatives, showcasing how innovation is unlocking new therapeutic and diagnostic possibilities. Experts will uncover cutting-edge advances in antibody-drug conjugates, bispecifics, nanobodies, and engineered antibodies, highlighting their enhanced specificity, efficacy, and versatility. The session will also examine how these novel formats are being applied beyond oncology, including in infectious diseases and autoimmune disorders. With an emphasis on cross-sector collaboration and real-world applications, this session promises a comprehensive view of how antibodies and antibody derivatives are delivering solutions to complex clinical challenges.
14:10 – 14:15

Opening Remarks

  • Lee-Cheng Liu, Founder, Chairman & President, EirGenix
14:15 – 14:40

TOPIC

  • EirGenix
14:40 – 15:05

TOPIC

  • OBI Pharma
15:05 – 15:30

TOPIC

  • Formosa Laboratories

16:00 – 17:30

Session A-7 – Innovative Developments and Cross-Disciplinary Applications of Antibody Derivatives

A follow on from Session A-6, again on fast-evolving antibody derivative technologies and their transformative potential across a wide range of therapeutic areas. 
15:40 – 16:05

TOPIC

  • PharmaEssentia
16:05 – 16:30

TOPIC

  • AP Biosciences
16:30 – 17:10

Panel Discussion

Moderator:
Lee-Cheng Liu, Founder, Chairman & President, EirGenix

Panelists:

  • EirGenix
  • OBI Pharma
  • Formosa Laboratories
  • PharmaEssentia
  • AP Biosciences

09:00 – 10:30

Session A-8 – Novel ADC-based Target Therapy

Session A-8 focuses on the rapid evolution of antibody-drug conjugates (ADCs) as a next-generation targeted therapy category. Experts will highlight innovations in linker chemistry, payload design, and tumor-specific targeting, leading to impressive ADC efficacy and safety profiles. The session will explore how novel ADCs are expanding beyond oncology into new therapeutic areas, offering highly selective treatment options with minimized systemic toxicity. Join us for this important session as leading experts in this field underscore ADCs’ growing role in redefining targeted therapies and improving patient outcomes.
09:00 – 09:05

Opening Remarks

  • Development Center for Biotechnology
09:05 – 09:25

OpenTopic TBC

  • Teiji Wada, Head of Research Platform and Vice President of Research Innovation Planning Department, Daiichi Sankyo
09:25 – 09:45

LYSward: An Engineering Platform for Generation of pH-Dependent Antibody Drug Conjugate to Enhance Antitumor Activity

  • Yu-Hsun Lo, Director of Protein Engineering Department, Institute of Biologics, Development of Center for Biotechnology
09:45 – 10:05

Topic TBC

  • Luke BI, Executive Director, Head of China BioA and APAC LCMS, Labcorp
10:10 – 10:30

Panel Discussion

Moderator:

  • Development Center for Biotechnology

Panelists:

  • Teiji Wada, Head of Research Platform and Vice President of Research Innovation Planning Department, Daiichi Sankyo
  • Yu-Hsun Lo, Director of Protein Engineering Department, Institute of Biologics, Development of Center for Biotechnology
  • Luke BI, Executive Director, Head of China BioA and APAC LCMS, Labcorp
  • Edward Y. H. Hsieh, R&D VP, Formosa labs

10:45 – 12:15

Session A-9 – Smart HealthCare

Session A-9 will explore the transformative impact of smart healthcare technologies on the entire healthcare delivery spectrum, beginning with a discussion on reshaping the future of healthcare through "Gen" medicine, emphasizing precision therapies and personalized treatments. Experts from the TMU Health System will share insights into AI applications in clinical practice, highlighting advancements in diagnostics, treatment planning, and patient monitoring. The session will also address the critical role of AI-driven cybersecurity in safeguarding healthcare systems. A regulatory overview will be provided on the latest FDA guidelines for smart healthcare and AI-based medical devices, ensuring compliance and innovation in this rapidly evolving field.
10:45 – 10:50

Opening Remarks

10:50 – 11:05

Reshaping the Future Healthcare with “Gen” Medicine

11:05 – 11:20

AI Applications in Clinical Practice: Insights from TMU Health System (TBC)

  • Mai-Szu Wu, President, Taipei Medical University
11:20 – 11:35

AI-Driven Cybersecurity in Healthcare Systems (TBC)

  • Wei-Bin Lee, CEO of the Hon Hai Research Institute and the Director of the Information Security Research Center, Hon Hai Technology Group (Foxconn®)
11:35 – 11:50

Regulatory Insights into the Latest FDA Guidelines on Smart Healthcare and AI-Based Medical Devices (TBC)

  • Chia-Hua Maggie Ho, COO, Amarex Taiwan
11:50 – 12:15

Panel Discussion

Moderator:

Panelists:

  • Ray-Jade Chen, Chairman, Board of Trustees, Taipei Medical University; Chair Professor, Taipei Medical University, Taiwan
  • Mai-Szu Wu, President, Taipei Medical University
  • Wei-Bin Lee, CEO of the Hon Hai Research Institute and the Director of the Information Security Research Center, Hon Hai Technology Group (Foxconn®)
  • Chia-Hua Maggie Ho, COO, Amarex Taiwan

12:25 – 13:55

Session A-10 – Global Trends and Clinical Applications of Whole Genome Sequencing

Session A-10 will explore the intersection of precision health and digital health. The session kicks off with a discussion on the latest digital health trends, highlighting emerging technologies and their global market impact. Experts will explore how precision health leverages data analytics to provide personalized care, promising to transform current treatment paradigms and patient outcomes. The session will also emphasize the importance of bridging gaps across disciplines, fostering collaboration between healthcare providers, tech innovators, and researchers. This session will highlight opportunities for interdisciplinary partnerships to drive advancements in precision medicine and global healthcare systems.
12:25 – 12:35

Opening Remarks

  • Representative from MOEA, Taiwan
  • Representative from American Institute in Taiwan (AIT)
  • Eric Y. Chuang, Vice President of ITRI, and General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI

Group Photo

12:35 – 13:20

Global National Genome Projects and Leveraging Lessons to Taiwan

The Value of WGS Data in Drug Discovery and Development

Transforming Precision Medicine with AI and Big Data

13:20 – 13:55

Panel Discussion: From Global Vision to Local Possibilities: Exploring the Future of WGS in Taiwan

Moderator:

  • Eric Y. Chuang, Vice President of ITRI, and General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI

Panelists:

14:10 – 17:00

Session A-11 – Special Session: Digital Health

Session A-11 will provide a comprehensive overview of the latest advancements and trends in digital health, focusing on innovative technologies shaping the future of healthcare delivery. Experts will examine the integration of wearables, mobile health apps, telemedicine, and AI-driven solutions to enhance patient care, improve outcomes, and optimize healthcare systems. The session will face up to challenges such as data privacy, regulatory hurdles, and ensuring equitable access to digital health tools. Special attention will be given to the potential of digital health in transforming chronic disease management, remote patient monitoring, and personalized treatments. Don't miss what promises to be a pivotal discussion of digital health ecosystems, both now and in the future. 
14:10 – 14:20

Opening Remarks

  • Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025; Honorary Chairman, Taiwan Bio Industry Organization (Taiwan BIO)
  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
14:20 – 14:40

National-Level Investments in Building the Precision Healthcare Industry

  • Chin-Ching Liu, Minister, National Development Council (Inviting)
14:40 – 15:00

Leveraging Health Big Data to Develop Diverse Smart Healthcare Solutions

  • Chung-Liang Shih, Director General, National Health Insurance Administration, Ministry of Health and Welfare
15:00 – 15:20

Smart Healthcare Cloud Ecosystem: Technology Integration and Future Prospects (TBC)

  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
15:20 – 15:35

Topic TBC

  • Amy McDonough, Managing Director, Strategic Health Solutions, Google Health (Inviting)
15:35 – 15:55

5G and IoT-Driven Smart Health Solutions

  • Chee Ching, President, Far EasTone Telecom
15:55 – 16:10

Breakthrough Applications and Challenges of AI in Smart Healthcare

  • Allen Chia En Lien, Chairman and CEO, Acer Medical (Inviting)
16:10 – 16:25

Topic TBC

  • Ed Deng, Co-Founder and CEO, Health2Sync
16:25 – 16:45

Applications of Digital Technology in Enhancing Healthcare Efficiency and Innovation

  • Nick Hung, Executive Vice President of Technology and Transformation, Deloitte Taiwan
16:45 – 17:30

Panel Discussion

Moderator:

  • Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025; Honorary Chairman, Taiwan Bio Industry Organization (Taiwan BIO)

Panelists:

  • Chin-Ching Liu, Minister, National Development Council (Inviting)
  • Chung-Liang Shih, Director General, National Health Insurance Administration, Ministry of Health and Welfare
  • Stan Shih, Chairman, StanShih Foundation; Co-founder & Honorary Chairman, Acer Group
  • Chee Ching, President, Far EasTone Telecom
  • Allen Chia En Lien, Chairman and CEO, Acer Medical (Inviting)
  • Ed Deng, Co-Founder and CEO, Health2Sync
  • Nick Hung, Executive Vice President of Technology and Transformation, Deloitte Taiwan